These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37844348)

  • 1. Omics profile of iPSC-derived astrocytes from Progressive Supranuclear Palsy (PSP) patients.
    Ravagnani FG; Valerio HP; Maués JHS; de Oliveira AN; Puga RD; Griesi-Oliveira K; Picosse FR; Ferraz HB; Catharino RR; Ronsein GE; de Carvalho Aguiar P
    Parkinsonism Relat Disord; 2023 Nov; 116():105847. PubMed ID: 37844348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative system biology analyses of CRISPR-edited iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTLD and PSP.
    Jiang S; Wen N; Li Z; Dube U; Del Aguila J; Budde J; Martinez R; Hsu S; Fernandez MV; Cairns NJ; ; ; Harari O; Cruchaga C; Karch CM
    Transl Psychiatry; 2018 Dec; 8(1):265. PubMed ID: 30546007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comprehensive Resource for Induced Pluripotent Stem Cells from Patients with Primary Tauopathies.
    Karch CM; Kao AW; Karydas A; Onanuga K; Martinez R; Argouarch A; Wang C; Huang C; Sohn PD; Bowles KR; Spina S; Silva MC; Marsh JA; Hsu S; Pugh DA; Ghoshal N; Norton J; Huang Y; Lee SE; Seeley WW; Theofilas P; Grinberg LT; Moreno F; McIlroy K; Boeve BF; Cairns NJ; Crary JF; Haggarty SJ; Ichida JK; Kosik KS; Miller BL; Gan L; Goate AM; Temple S;
    Stem Cell Reports; 2019 Nov; 13(5):939-955. PubMed ID: 31631020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-nucleus chromatin accessibility profiling highlights distinct astrocyte signatures in progressive supranuclear palsy and corticobasal degeneration.
    Briel N; Ruf VC; Pratsch K; Roeber S; Widmann J; Mielke J; Dorostkar MM; Windl O; Arzberger T; Herms J; Struebing FL
    Acta Neuropathol; 2022 Oct; 144(4):615-635. PubMed ID: 35976433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report of a patient with unclassified tauopathy with molecular and neuropathological features of both progressive supranuclear palsy and corticobasal degeneration.
    Koga S; Metrick MA; Golbe LI; Santambrogio A; Kim M; Soto-Beasley AI; Walton RL; Baker MC; De Castro CF; DeTure M; Russell D; Navia BA; Sandiego C; Ross OA; Vendruscolo M; Caughey B; Dickson DW
    Acta Neuropathol Commun; 2023 Jun; 11(1):88. PubMed ID: 37264457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gradient subthalamic neurodegeneration and tau pathology in the hypoglossal nucleus as essential pathological markers of progressive supranuclear palsy - Richardson syndrome.
    Homma T; Mochizuki Y; Hara M; Kamei S; Mizutani T; Takubo H; Isozaki E; Takahashi M; Komori T; Hao H
    Rev Neurol (Paris); 2020 May; 176(5):353-360. PubMed ID: 32247606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heavy metals contaminating the environment of a progressive supranuclear palsy cluster induce tau accumulation and cell death in cultured neurons.
    Alquezar C; Felix JB; McCandlish E; Buckley BT; Caparros-Lefebvre D; Karch CM; Golbe LI; Kao AW
    Sci Rep; 2020 Jan; 10(1):569. PubMed ID: 31953414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of the astrocytic tau pathology to synapse loss in progressive supranuclear palsy and corticobasal degeneration.
    Briel N; Pratsch K; Roeber S; Arzberger T; Herms J
    Brain Pathol; 2021 Jul; 31(4):e12914. PubMed ID: 33089580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-specific MAPT gene expression is preserved in neuronal and glial tau cytopathologies in progressive supranuclear palsy.
    Forrest SL; Lee S; Nassir N; Martinez-Valbuena I; Sackmann V; Li J; Ahmed A; Tartaglia MC; Ittner LM; Lang AE; Uddin M; Kovacs GG
    Acta Neuropathol; 2023 Sep; 146(3):395-414. PubMed ID: 37354322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delineation of early changes in cases with progressive supranuclear palsy-like pathology. Astrocytes in striatum are primary targets of tau phosphorylation and GFAP oxidation.
    Santpere G; Ferrer I
    Brain Pathol; 2009 Apr; 19(2):177-87. PubMed ID: 18462470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of astrocytic pathology in stem cell models of primary tauopathies.
    Fiock KL; Hook JN; Hefti MM
    Acta Neuropathol Commun; 2023 Oct; 11(1):161. PubMed ID: 37803326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic bases of Progressive Supranuclear Palsy: the MAPT tau disease.
    Borroni B; Agosti C; Magnani E; Di Luca M; Padovani A
    Curr Med Chem; 2011; 18(17):2655-60. PubMed ID: 21568901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological tau signatures and nuclear alterations in neurons, astrocytes and microglia in Alzheimer's disease, progressive supranuclear palsy, and dementia with Lewy bodies.
    Montalbano M; Majmundar L; Sengupta U; Fung L; Kayed R
    Brain Pathol; 2023 Jan; 33(1):e13112. PubMed ID: 36054524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological and Clinical Spectrum of Progressive Supranuclear Palsy: With Special Reference to Astrocytic Tau Pathology.
    Yokoyama Y; Toyoshima Y; Shiga A; Tada M; Kitamura H; Hasegawa K; Onodera O; Ikeuchi T; Someya T; Nishizawa M; Kakita A; Takahashi H
    Brain Pathol; 2016 Mar; 26(2):155-66. PubMed ID: 25974705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropathology of variants of progressive supranuclear palsy.
    Dickson DW; Ahmed Z; Algom AA; Tsuboi Y; Josephs KA
    Curr Opin Neurol; 2010 Aug; 23(4):394-400. PubMed ID: 20610990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology.
    Heckman MG; Brennan RR; Labbé C; Soto AI; Koga S; DeTure MA; Murray ME; Petersen RC; Boeve BF; van Gerpen JA; Uitti RJ; Wszolek ZK; Rademakers R; Dickson DW; Ross OA
    JAMA Neurol; 2019 Jun; 76(6):710-717. PubMed ID: 30882841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latent trait modeling of tau neuropathology in progressive supranuclear palsy.
    Kouri N; Murray ME; Reddy JS; Serie DJ; Soto-Beasley A; Allen M; Carrasquillo MM; Wang X; Castanedes MC; Baker MC; Rademakers R; Uitti RJ; Graff-Radford NR; Wszolek ZK; Schellenberg GD; Crook JE; Ertekin-Taner N; Ross OA; Dickson DW
    Acta Neuropathol; 2021 May; 141(5):667-680. PubMed ID: 33635380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy.
    Allen M; Wang X; Serie DJ; Strickland SL; Burgess JD; Koga S; Younkin CS; Nguyen TT; Malphrus KG; Lincoln SJ; Alamprese M; Zhu K; Chang R; Carrasquillo MM; Kouri N; Murray ME; Reddy JS; Funk C; Price ND; Golde TE; Younkin SG; Asmann YW; Crook JE; Dickson DW; Ertekin-Taner N
    Acta Neuropathol; 2018 Nov; 136(5):709-727. PubMed ID: 30136084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial aggregation of parkinsonism in progressive supranuclear palsy.
    Donker Kaat L; Boon AJ; Azmani A; Kamphorst W; Breteler MM; Anar B; Heutink P; van Swieten JC
    Neurology; 2009 Jul; 73(2):98-105. PubMed ID: 19458322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurate digital quantification of tau pathology in progressive supranuclear palsy.
    Pansuwan T; Quaegebeur A; Kaalund SS; Hidari E; Briggs M; Rowe JB; Rittman T
    Acta Neuropathol Commun; 2023 Nov; 11(1):178. PubMed ID: 37946288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.